Por favor, use este identificador para citar o enlazar este ítem: http://hdl.handle.net/10637/15202
Registro completo de metadatos
Campo DC Valor Lengua/Idioma
dc.contributor.otherUniversidad San Pablo-CEU. Facultad de Medicina-
dc.creatorAgache, Ioana-
dc.creatorAkdis, Cezmi A.-
dc.creatorAkdis, Mubeccel-
dc.creatorBrockow, Knut-
dc.creatorChivato Pérez, Tomás-
dc.creatorEiwegger, Thomas-
dc.creatorEyerich, Kilian-
dc.creatorGiménez-Arnau, Ana-
dc.creatorGutermuth, Jan-
dc.creatorGuttman-Yassky, Emma-
dc.creatorMaurer, Marcus-
dc.creatorOgg, Graham-
dc.creatorOng, Peck Y.-
dc.creatorO’Mahony, Liam-
dc.creatorSchwarze, Jürgen-
dc.creatorWarner, Amena-
dc.creatorWerfel, Thomas-
dc.creatorPalomares, Oscar-
dc.creatorJutel, Marek-
dc.creatorGiacco, Stefano del-
dc.date.accessioned2024-01-29T09:59:56Z-
dc.date.available2024-01-29T09:59:56Z-
dc.date.issued2022-
dc.identifier.citationAgache I, Akdis CA, Akdis M, et al. EAACI Biologicals Guidelines—Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12–17 years old. Allergy. 2022;77:17– 38. https://doi.org/10.1111/all.15030en_EN
dc.identifier.issn1398-9995-
dc.identifier.urihttp://hdl.handle.net/10637/15202-
dc.description.abstractChronic spontaneous urticaria (CSU) imposes a significant burden on patients, families and healthcare systems. Management is difficult, due to disease heterogeneity and insufficient efficacy of classical drugs such as H1R-antihistamines. Better understanding of the mechanisms has enabled a stratified approach to the management of CSU, supporting the use of targeted treatment with omalizumab. However, many practical issues including selection of responders, the definition of response, strategies to enhance the responder rate, the duration of treatment and its regimen (in the clinic or home-based) and its cost-effectiveness still require further clarification. The EAACI Guidelines on the use of omalizumab in CSU follow the GRADE approach in formulating recommendations for each outcome. In addition, future therapeutic approaches and perspectives as well as research priorities are discussed.en_EN
dc.formatapplication/pdf-
dc.language.isoen-
dc.publisherWiley-
dc.relation.ispartofAllergy-
dc.rightshttp://creativecommons.org/licenses/by-nc-nd/4.0/deed.es-
dc.subjectChronic spontaneous urticariaen_EN
dc.subjectGRADEen_EN
dc.subjectGuidelineses_EN
dc.subjectOmalizumaben_EN
dc.titleEAACI Biologicals Guidelines—Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12–17 years olden_EN
dc.typeArtículo-
dc.centroUniversidad San Pablo-CEU-
Aparece en las colecciones: Medicina




Los ítems de DSpace están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.